Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents
- PMID: 31210108
- DOI: 10.2174/1568026619666190618130008
Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents
Abstract
Microtubules are essential for the mitotic division of cells and have been an attractive target for antitumour drugs due to the increased incidence of cancer and significant mitosis rate of tumour cells. In the past few years, tubulin-colchicine binding site, as one of the three binding pockets including taxol-, vinblastine- and colchicine-binding sites, has been focused on to design tubulin-destabilizing agents including inhibitors, antibody-drug conjugates and degradation agents. The present review is the first to cover a systemic and recent synopsis of tubulin-colchicine binding site agents. We believe that it would provide an increase in our understanding of receptor-ligand interaction pattern and consciousness of a series of challenges about tubulin target druggability.
Keywords: Antibody-drug conjugates; Antimitotic; Antitumour; Degraders; Inhibitors; Microtubules; Tubulin-colchicine binding site..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures.Future Med Chem. 2017 Oct;9(15):1765-1794. doi: 10.4155/fmc-2017-0100. Epub 2017 Sep 20. Future Med Chem. 2017. PMID: 28929799 Review.
-
Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.Med Res Rev. 2008 Jan;28(1):155-83. doi: 10.1002/med.20097. Med Res Rev. 2008. PMID: 17464966 Review.
-
The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.J Mol Biol. 2014 Apr 17;426(8):1848-60. doi: 10.1016/j.jmb.2014.02.005. Epub 2014 Feb 11. J Mol Biol. 2014. PMID: 24530796
-
A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.Cancer Lett. 2020 Dec 28;495:22-32. doi: 10.1016/j.canlet.2020.08.040. Epub 2020 Sep 12. Cancer Lett. 2020. PMID: 32931884
-
Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization.Eur J Med Chem. 2011 Aug;46(8):3519-25. doi: 10.1016/j.ejmech.2011.05.020. Epub 2011 May 13. Eur J Med Chem. 2011. PMID: 21621885
Cited by
-
Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.MedComm (2020). 2024 Jul 28;5(8):e671. doi: 10.1002/mco2.671. eCollection 2024 Aug. MedComm (2020). 2024. PMID: 39070179 Free PMC article. Review.
-
Benzotriazole Substituted 2-Phenylquinazolines as Anticancer Agents: Synthesis, Screening, Antiproliferative and Tubulin Polymerization Inhibition Activity.Curr Cancer Drug Targets. 2023;23(4):278-292. doi: 10.2174/1568009623666221028121906. Curr Cancer Drug Targets. 2023. PMID: 36306454
-
Angiogenesis and anti-leukaemia activity of novel indole derivatives as potent colchicine binding site inhibitors.J Enzyme Inhib Med Chem. 2022 Dec;37(1):652-665. doi: 10.1080/14756366.2022.2032688. J Enzyme Inhib Med Chem. 2022. PMID: 35109719 Free PMC article.
-
New Heterocyclic Combretastatin A-4 Analogs: Synthesis and Biological Activity of Styryl-2(3H)-benzothiazolones.Pharmaceuticals (Basel). 2021 Dec 20;14(12):1331. doi: 10.3390/ph14121331. Pharmaceuticals (Basel). 2021. PMID: 34959731 Free PMC article.
-
Protein Modelling and Molecular Docking Analysis of Fasciola hepatica β-Tubulin's Interaction Sites, with Triclabendazole, Triclabendazole Sulphoxide and Triclabendazole Sulphone.Acta Parasitol. 2023 Sep;68(3):535-547. doi: 10.1007/s11686-023-00692-z. Epub 2023 Jun 18. Acta Parasitol. 2023. PMID: 37330945
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous